Drug intelligence / Profile preview

AVX-201

Development stage: Discontinued
Lead developer: Aravax
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

AVX-201 is a discontinued oral prophylactic vaccine developed by Aviex Technologies for the prevention of Influenza A virus infections, specifically intended for pandemic influenza. The vaccine was designed as an immunostimulant using the company's proprietary YS1646 platform, which utilizes a live-attenuated Salmonella typhimurium bacterial vector to deliver antigens and stimulate a protective immune response. Development reached the preclinical stage in the United States, but the project was discontinued as of September 2023.

Other names: PROPHYLACTIC PANDEMIC INFLUENZA VACCINE

Beyond the preview

Go deeper on AVX-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVX-201.